Early Detection of Acute Drug-Induced Liver Injury in Mice by Non-invasive NIR Fluorescence Imaging

Authors: Kristine O. Vasquez & Jeffrey D. Peterson

Affiliations: KOV & JDP, PerkinElmer Inc., 68 Elm Street, Hopkinton MA 01748
Running title: Optical Imaging of Drug-Induced Liver Injury

Corresponding Author Contact Information:

Jeffrey D. Peterson, Ph.D.
PerkinElmer Life Sciences and Technology
68 Elm Street, Hopkinton MA 01748
Phone: (508) 589-7542
jeff.peterson@perkinelmer.com

# text pages: 36

# tables: 1

# figures: 10

# references: 51

# words: 250 abstract

745 introduction

1887 discussion

List of abbreviations: NIR, near infrared; DILI, drug-induced liver injury

Recommended section: Toxicology
ABSTRACT

Hepatocellular and cholestatic forms of drug induced liver injury (DILI) are major reasons for late stage termination of small molecule drug discovery research projects. Biochemical serum markers are limited in their ability to sensitively and specifically detect both of these common DILI forms in preclinical models, and tissue-specific approaches to assessing this are labor intensive, requiring extensive animal dosing, tissue preparation, and pathology assessment. In vivo fluorescent imaging offers non-invasive detection of biological changes detected directly in the livers of living animals. Three different near infrared fluorescent imaging probes, specific for cell death (Annexin-Vivo 750), matrix metalloproteases (MMPSense 750 FAST), and transferrin receptor (Transferrin-Vivo 750) were used to measure the effects of single bolus intraperitoneal doses of four different chemical agents known to induce liver injury. Hepatocellular injury-inducing agents, thioacetamide and acetaminophen, showed optimal injury detection with probe injection at 18-24 h, the liver cholestasis-inducing drug rifampicin required early probe injection (2 h), and chlorpromazine, which induces mixed hepatocellular/cholestatic injury, showed injury with both early and late injection. Different patterns of liver responses were seen among these different imaging probes, and no one probe detected injury by all four compounds. By using a cocktail of these three near infrared fluorescent imaging probes, all labeled with 750 nm fluorophores, each of the four different DILI agents induced comparable tissue injury within the liver region as assessed by epifluorescence imaging. A strategy of probe cocktail injection in separate cohorts at 2 h and at 20-24 h allowed the effective detection of drugs with either early- or late-onset injury.
Introduction

Drug-induced liver injury (DILI) is the leading reason for termination of drug discovery research projects, is a significant concern in attrition of new drug molecules reaching phase III clinical trials, is the major reason for US Food and Drug Administration (FDA) withdrawal of drugs from the market after approval, and accounts for more than 50% of acute liver failure cases in the United States (Bissell et al., 2001). Toxicity-related attrition in drug development can occur at all stages of the preclinical research process, with later stage identification of toxicity obviously being the most costly, so early elimination of hepatotoxicity-inducing compounds during drug discovery and preclinical development is an important priority.

One new tactic in toxicology is to focus on identifying perturbations of relevant biomarkers associated with important biological functions and pathways (Gibb, 2008; Bhattacharya et al., 2011; Krewski et al., 2011). This could offer some potential advantages over conventional toxicology approaches in both sensitivity and ease of application. Depending on the drug being tested, and its potential toxic mechanism(s), a variety of different biological pathway changes can occur in liver tissue, including those indicating direct hepatocyte injury (apoptosis/necrosis), oxidative stress, vascular or microvascular injury, induction of innate or cognate immunity/inflammation, and DNA damage. Within each of these mechanisms are multiple signaling pathways and biomarkers that could serve as indicators of drug effects, so a strategy of pathway/biomarker profiling has the potential for the sensitive detection of drug-induced changes for early stage screening. Generally this systems-based toxicology strategy utilizes in vitro experimental models and addresses dozens of biomarkers from interconnected or parallel networks, however our hypothesis was that such an approach could be adapted for in vivo use in a scaled down fashion by using simultaneous detection of a few key biomarker responses. This should retain the concept of screening for different types of adverse biological responses, rather than relying on grosser tissue phenotypic changes, but opens up the possibility of using non-invasive rodent imaging strategies.
Recent advances in optical imaging and near-infrared (NIR) probes (Weissleder and Ntziachristos, 2003; Korideck and Peterson, 2009; Krautz-Peterson et al., 2009; Kossodo et al., 2010; Peterson et al., 2010; Bao et al., 2012; Lin et al., 2012; Zhang et al., 2012; Eaton et al., 2013; Daghighi et al., 2014), have shown the benefit of biological readouts, rather than phenotypic or anatomical readouts, in preclinical drug efficacy research. Although imaging of preclinical models of safety/toxicology has not been pursued extensively to date, the ability to use fluorescent imaging probes that detect and quantify a variety of biological activities has considerable potential in this area as well (Amoozegar et al., 2012; Shuhendler et al., 2014; Peterson, 2016). In the present studies, three different types of NIR fluorescent probes, Annexin-Vivo™ 750 (AV-750), MMPSense® 645 or 750 (MMP-645, MMP-750), and Transferrin-Vivo™ 750 (TfV-750), specific for cell death, matrix metalloprotease activity (inflammation) and transferrin receptor (metabolic activity) expression, respectively, were found to be excellent tools for detecting/characterizing drug-induced tissue injury in general, and DILI in particular. A single dose of well characterized hepatocellular injury-inducing agents, thioacetamide (300 mg/kg) or acetaminophen (300 mg/kg), showed late induction of acute injury (optimal probe injection ~18-22 h), the liver cholestasis-inducing drug rifampicin (300 mg/kg) showed a very early liver response (optimal probe injection ~2 h), and chlorpromazine (100 mg/kg), which induces mixed hepatocellular/cholestatic injury, showed both early and late signals, with different patterns of liver responses among these different probes seen for the four different chemical agents. By using a cocktail of these three near infrared fluorescent imaging probes (AMT-750), all labeled with 750 nm fluorophores, each of the four different chemical agents showed comparable total fluorescent signal within the liver region by epifluorescence imaging, offering a potentially useful universal DILI imaging strategy to be applied to compounds of unknown DILI potential or mechanism. The use of AngioSense® 680 (AS-680), in combination with the AMT-750 cocktail of probes, provided further information regarding drug-induced vascular changes and allowed correction for any contribution of passive accumulation of the 750 nm probe cocktail. A strategy of probe injection in separate cohorts at 2 h and at 20-24 h allowed the sensitive identification of chemical agents with either early- or late-onset injury to limit the possibility of false negative results. Compared to conventional plasma/serum assays, in vivo imaging can offer fast, quantitative imaging results that directly assess
the tissue of interest. Our results to date demonstrate the potential of optical imaging to assess possible drug liver toxicity early in drug discovery programs.

Materials and Methods

Experimental animals. For drug-induced liver toxicity studies, male BALB/c mice (7-10 weeks of age) and C57BL/6 mice (7-8 weeks of age to minimize skin pigment interference after 8 weeks) were obtained from Charles River (Wilmington, MA) and maintained in a controlled environment (72°F; 12:12-h light-dark cycle) under specific-pathogen free conditions with water and low fluorescence chow (Envigo, Cambridgeshire, United Kingdom) provided ad libitum. C57BL/6 mice induced with acetaminophen were fasted overnight (approximately 18 h) prior to drug administration. For this particular treatment, the use of C57BL/6 mice was essential, as well as the use of males; female C57BL/6 mice and mice of other strains show low liver toxicity under the conditions explored in this research (Duan et al., 2016). For all other treatments, male BALB/c mice were used. All experiments were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol (#04-0512) was approved by PerkinElmer’s IACUC guidelines for animal care and use. No invasive or surgical procedures were used in these studies, but all imaging activities were performed under appropriate anesthesia to minimize animal distress.

Fluorescent probes for the detection of tissue injury. Four commercially available NIR fluorescent imaging probes (PerkinElmer Inc., Hopkinton, MA) were used to detect drug-induced tissue injury. AV-750 (fluorophore-labeled Annexin V protein) was used to detect apoptosis and early necrosis in affected tissues. MMP-645 and MMP-750 probes (fluorophore-labeled MMP substrate peptide [P-L-G-V-R]), pan-specific for the matrix metalloprotease family of enzymes, were used to detect secretion of these proteases by inflammatory cells. The Transferrin-Vivo 750 (TfV-750) probe (fluorophore-labeled transferrin protein) was used to detect
changes in transferrin receptor expression indicative of metabolic changes within the liver. AS-680 is a vascular probe designed to detect blood leakage into tissue either due to edema or vascular injury. For studies where individual imaging probes were used, the standard recommended dose from the product insert was used. Fluorescence was measured at recommended time points: 24 h post-injection for all probes except for AV-750, which was measured at 2 h (with signal still present at 24 h). For studies involving a cocktail of imaging probes (AMT-750) a 3:8:1 ratio (AV-750:MMP-750:TfV-750), i.e. 1.5 nmol of AV-750 was combined with 4 nmol MMP-750, and 0.5 nmol TfV-750 for each mouse injection. This maximized specific drug-induced signal while minimizing background liver and kidney signal. AMT-750 imaging was performed 24 h post-probe injection. The standard 2 nmol/mouse dose of AS-680 was added to the imaging cocktail in the final imaging studies.

A variety of other NIR fluorescent imaging probes are available that capture different molecular aspects of fibrosis, inflammation, calcification, glomerular filtration rate, and gastric emptying rate associated with liver, vascular, kidney and gastric tissue damage induced by drugs (Table I).

**DILI studies.** A panel of small chemical compounds with established toxicity profiles were used in acute, single dose studies in BALB/c or C57BL/6 mice.

- **Thioacetamide (TAA)** is an organosulfur compound that has been used as a substitute for hydrogen sulfide, as a stabilizer of motor fuel, and as a topical preventative for mold growth on fruit. It is known as a class 2B carcinogen that also induces marked hepatocellular toxicity in animals (Wang et al., 2004; Ackerman et al., 2015).

- **Rifampicin (RMP)** is a widely used antimicrobial agent that is a crucial component in treatment regimens for tuberculosis. This drug causes hepato- and nephrotoxicity as well as abdominal cramps and stomach distension (Zitkova et al., 1982; Katz and Lor, 1986; Zargar et al., 1990; Tassaduq et al., 2011).
Chlorpromazine (CPZ) is widely used as a sedative or anti-emetic as well as one of the primary antipsychotic medications used to treat schizophrenia. This drug is known to induce acute inflammation-mediated cholestatic liver injury (Mullock et al., 1983) and changes in kidney function Berg, 1976 #123).

Acetaminophen (APAP) is an over-the-counter medication that is widely used for treatment of pain and fever. Acute overdoses are well known to cause rapid, potentially fatal, hepatocellular injury and it is the leading cause of acute liver failure in the western world due to either deliberate overdose, accidental overdose, or other risk factors with therapeutic dosing (Maddox et al., 2010; Ging et al., 2016; Yoon et al., 2016). This drug induces marked hepatocellular toxicity in C57BL/6 mice with significant variations between mouse strains (McGill et al., 2012; Duan et al., 2016).

Acetaminophen (Sigma-Aldrich, catalog A7085) was freshly prepared in PBS at a concentration of 20 mg/mL. The PBS was pre-heated in a 55°C water bath to facilitate dissolving the powder. Rifampicin (RMP, Sigma catalog # R3501) was prepared in a complexing agent, 2-Hydroxypropyl)-β-cyclodextrin solution (Sigma catalog # H 5784), at a concentration of 10 mg/mL. Chlorpromazine (CPZ, Sigma-Aldrich catalog # C8138) was prepared in water at a concentration of 20 mg/mL. Thioacetamide (TAA, Sigma catalog # 163678) was prepared in water at a concentration of 20 mg/mL.

Mice were injected IP with chemical compounds as a single bolus dose and injected at different times post-treatment with NIR fluorescent imaging probes or probe cocktail. Immediately prior to imaging, mice were anesthetized using isoflurane inhalation and depilated to minimize fur interference with fluorescent signal. Nair lotion (Church and Dwight Co., Inc., Princeton, NJ) was applied thickly on skin over the torso (front, back, and sides) of each mouse, rinsed off with warm water, and reapplied until all fur was removed. Imaging was performed on the IVIS® SpectrumCT (PerkinElmer, Inc., Hopkinton MA) by 2D epifluorescence imaging at indicated times after probe injection to optimize readouts for DILI. In preliminary studies, mice were injected IP with a range of doses of liver injury-causing compounds, from 30-600 mg/kg (data not shown). From this
data, a dose of 300 mg/kg was selected for RMP, APAP, and TAA, and a lower dose of 100 mg/kg was chosen for CPZ to minimize excessive vascular damage caused at higher doses. BALB/c female mice were used for all compounds except for APAP, which is known to require C57BL/6 male mice for optimal elicitation of liver injury.

**Ex vivo serum ALT & ALP assessment.** Serum was collected from BALB/c mice treated with single IP doses of CPZ (100 mg/kg), RMP (300 mg/kg), TAA (100 mg/kg), and APAP (500 mg/kg) 24 h following dosing. Samples were assayed for alanine transaminase (QuantiChrom™ Alkaline Phosphatase Assay Kit, BioAssay Systems, Hayward CA) and alkaline phosphatase (EnzyChrom™ Alanine Transaminase Assay Kit, BioAssay Systems, Hayward CA) using the manufacturer’s protocols.

**Ex vivo fluorescence assessment of affected tissues.** After animals were imaged in vivo, they were sacrificed by carbon dioxide asphyxiation. The organs (brain, heart, lungs, liver, pancreas, spleen, stomach, intestines, kidneys, fat, and skin) were removed post-mortem. Epifluorescence images of the organs were acquired followed by tissue fixation in 10% formalin.

**Histopathology.** A select set of tissues (liver, kidneys, stomach, heart) were fixed in 10% Neutral Buffered Formalin (NBF) for 24 hours at 20°C, followed by storage in 70% ethanol. Tissues were then paraffin-embedded, sectioned (4 µm), and stained with hematoxylin & eosin (H&E) for general evaluation of pathologic changes.

**Statistical analysis.** Data are presented as the mean ± standard error of the mean. Significance analysis was conducted using ANOVA with Dunnett’s post-test in comparison to untreated control animals/tissues. \( P < 0.05 \) was considered significant.
RESULTS

Modes of optical imaging for detection and quantification of liver fluorescence. A unique approach to liver injury measurement, using fluorescence imaging, was assessed that could provide a means for rapid screening of liver biology changes, rather than looking for overt tissue changes, using minimal compound in a single high-dose bolus-injection model in mice. One of the most obvious biological responses to explore as a readout was cell death, so we used an Annexin V-based NIR fluorescent imaging probe (AV-750) that has been used effectively in cancer treatment research (Zhao et al., 2015) and in preliminary liver injury studies (Peterson, 2016). Such a probe should be useful for assessing drugs known to induce hepatocellular liver toxicity which involves direct induction of cytotoxic liver apoptosis/necrosis. To assess whether optical imaging can be used to detect acute drug-induced damage in the liver, a variation of a well-established mouse model of DILI was used; male C57BL/6 mice were injected IP with a single bolus dose of 500 mg/kg acetaminophen (APAP) followed 24 h later by IV injection of the NIR fluorescent AV-750 imaging probe to detect apoptosis/necrosis in the liver. Three modes of optical imaging were used (Fig. 1): 1) 2D epifluorescence imaging, 2) 2D transillumination fluorescence imaging, and 3) 3D tomographic imaging. Epifluorescence provided a rapid and robust approach for imaging 5 animals at a time, although this approach was limited in its ability to detect deep tissue signal. Transillumination (2D) imaging used a moving point light source placed behind the subject, yielding a composite image that revealed a blending of deep tissue and superficial signal. Tomography (3D) used a similar transillumination approach, but rather than blending the results in a 2D representation, the results from multiple image acquisitions were run through a mathematical algorithm to model 3D localization within the body of the subject. All three of these approaches were highly effective in detecting increases in AV-750 liver binding induced by APAP (Fig. 1A). Tomography was the most useful approach for detecting and discriminating liver and kidney signal, however it was limited to one mouse at a time and required ~20 minutes per mouse. Epifluorescence imaging offered the best combination of rapid multiple animal imaging and sensitive detection of liver signal. The 2D transillumination approach was least effective in that image acquisition was relatively slow and the final results yielded kidney signal overlap.
with the analysis of liver fluorescence. Quantitatively, all three approaches effectively showed increased AV-750 signal as compared to control mice (Fig. 1B). Epifluorescence and tomographic approaches correlated well with each other, and both correlated well with quantification of 2D epifluorescence signal in liver tissues ex vivo (data not shown).

Epifluorescence profiling of 3 NIR fluorescent imaging probes in mice treated with 4 different liver injury-inducing chemical agents. Preliminary studies using AV-750 to assess different DILI-inducing chemical agents, suggested that this probe is a sensitive detector of hepatocellular toxicity (Peterson, 2016) but may not be as effective in detecting other forms of liver injury such as cholestasis. In part, this may be due to our stringent requirement that our imaging system/probes detect liver changes following only a single compound administration, and in part this could be attributed to the additional mechanistic complexity in other forms of DILI in which additional time may be needed for inflammation or bile duct blockage events to occur.

Other biomarkers, for which there are imaging probes, are known to change in expression during different types of liver injury. For example, iron is an essential nutrient that is tightly regulated by the liver, and excessive iron uptake is one of the major mechanisms contributing to increased steatohepatitis, fibrosis, and cirrhosis (Anderson and Shah, 2013). Transferrin is generated in the liver as the major serum iron-binding protein in the body, and both transferrin (Amacher et al., 2005) and transferrin receptor (Cairo and Pietrangelo, 1995; Izawa et al., 2014) have been found to change expression during chemically-induced liver injury. Matrix metalloproteases (MMP) have also been implicated as biomarkers of liver injury, as indicators of both inflammation and fibrosis. In particular, MMP-2 and -9 have been shown to play a role in CCl4-induced hepatic fibrosis (Domitrovic et al., 2013; Al-Olayan et al., 2014). To assess the potential benefit of combined screening for cell death, MMP activity, and transferrin-receptor expression on the detection of DILI, we used fluorescent imaging probes specific for these biomarkers (AV-750, MMP-645, and TfV-750, respectively) to image the livers of animals receiving four different liver injury-inducing chemical compounds. Two of these,
thioacetamide (TAA) and APAP, are known to induce hepatocellular injury (Ackerman et al., 2015; McGill et al., 2012); a third drug, rifampicin (RMP), predominantly induces liver cholestasis (Zitkova et al., 1982; Katz and Lor, 1986; Zargar et al., 1990); and a fourth drug, chlorpromazine (CPZ), induces mixed hepatocellular/cholestasis injury (Mullock et al., 1983). Serum ALT:ALP ratios can provide a rough mechanistic assessment with hepatocellular injury defined as a ratio $> 5$, cholestasis $< 2$, and mixed hepatocellular/cholestasis 2 to 5. Our serum ALT:ALP results (from mice receiving single IP bolus doses of chemical compounds) agreed well with previous publications regarding mechanistic interpretation of each of the chemical agents; ALT:ALP ratios for APAP (500 mg/kg) and TAA (100 mg/kg) were $>15$, RMP (300 mg/kg) was 0.5, and CPZ (100 mg/kg) was 1.8.

Whole mouse epifluorescence imaging (Figure 2) was used to detect accumulation of AV-750, MMP-645, and TfV-750 in the liver regions of different cohorts of mice by injecting these probes at different times following treatment (2, 5, 18-22, and 42 h). AV-750 was imaged 2 h after probe injection, and the other two probes were imaged 24 h after probe injection to achieve optimal probe performance with regard to peak signal and maximal washout of unbound probe. In all cases, based on PK and biodistribution, the biological changes detected likely occurred within a 0-10 h time frame relative to probe injection, even in instances where actual images were acquired at 24 h. The apparent kinetics of liver change differed between the different chemical agents and the different probes. Interestingly, earlier changes were associated with those chemical agents known to induce cholestasis (i.e. RMP and CPZ), whereas later changes were associated with chemically induced hepatocellular damage (i.e. APAP and TAA). CPZ, which is known to induce mixed cholestasis/hepatocellular liver injury showed both early and late liver signal. Although AV-750 was optimally imaged 2 h post-injection, additional studies indicated good probe retention in the liver up to 24 h (data not shown), allowing the possibility of aligning imaging timepoints between different probes more easily. Quantification of results for each of these chemical agent/probe combinations (Figure 3) was performed in datasets representing the peak response, which was 2 h (post-treatment) for RMP, 42 h for CPZ, 22 h for APAP, and 42 h for TAA. Numbers reflect fold increases over background following threshold correction for
background signal to best adjust to absolute magnitude differences attributable to both probe and fluorophore wavelength. RMP signal was dominated by MMP-645 activity, CPZ showed dominant MMP-645 and TfV-750 signal, and the two hepatocellular-toxicity inducing chemical agaents (APAP and TAA) were generally dominated by AV-750 +/- TfV-750 signal.

**Testing of NIR fluorescent three-probe cocktail for general liver injury imaging.** The effectiveness of AV-750, MMP-645, and TfV-750, each showing some level of detection of liver injury induced by 4 different chemical agents, raised the possibility of using them in combination. One strategy would be to use them each on a different spectral channel, with 3-plex imaging providing 3 independent datasets. Alternatively, one could pursue a simpler approach by combining all three probes as a cocktail in the same spectral channel. The second approach fits well with our overall concept of a simple screening paradigm, used early in the drug discovery process, that requires only small amounts of compounds and small numbers of mice. A cocktail of these imaging probes was generated from 1.5 nmol/mouse of AV-750, 4 nmol/mouse MMP-750, and 0.5 nmol/mouse TfV-750 based on preliminary studies designed to maximize liver signal while minimizing normal background liver/kidney signal (data not shown). This cocktail of probes (AMT-750) was tested in mice receiving single bolus doses of RMP, CPZ, APAP, or TAA; AMT-750 was injected at appropriate time points after chemical agent bolus (based on achieving maximal AV-750 signal), and imaging was performed 24 h later. All four treatment groups showed clear, liver region fluorescence by 2D epifluorescence imaging and signals were statistically significant as compared to control animals, ranging from 5-7-fold increases (Fig. 4). Fluorescence increases were comparable with the different chemical agents, suggesting that the AMT-750 cocktail effectively and equivalently detected hepatocellular, cholestasis, and mixed liver injury in mice. Ex vivo liver tissue imaging confirmed the apparent liver changes seen non-invasively, however other sources of fluorescence within the mid-torso seemed to contribute to the signal since RMP and CPZ liver tissue signal was much lower than expected. To reconcile this discrepancy, we examined other tissues that could contribute to liver region imaging, including stomach, pancreas, spleen, and abdominal fat. It was interesting to note that both RMP and
CPZ mice showed increased kidney signal which was sufficiently bright to contribute to the liver region imaging results. These results led us to two critical conclusions; 1) epifluorescence is a fast and effective screening approach, but results need to be interpreted carefully, and 2) the AMT-750 cocktail has the potential to detect not only DILI but also injury to other tissues.

A comprehensive screening paradigm using AMT-750 to detect chemically-induced injury to liver and other tissues in vivo and ex vivo. Imaging results from the studies represented in Figures 1-4 established an effective protocol for acquiring quantification of biological liver changes, however it also involved extensive pilot studies to establish the right doses, conditions, and time points tailored to the agents tested. As our goal was to establish an early drug discovery-stage screening process for assessing potential liabilities of new chemical entities, it was important to establish a testing paradigm that takes into account additional factors such as contribution from non-hepatic tissues, the impact of non-specific accumulation, and the need to capture the right time point. In addition, interpretation of AMT-750 results can be compromised by non-specific accumulation in tissue due to increased vascular leak, so we included AS-680 to allow for subtraction or normalization to compensate for vascular effects. In our experience, the optimal time for injecting imaging probes (post-treatment) will generally be at either 2 h or 24 h, with liver injury induction producing good liver AMT-750 signal when imaged 24 h after at least one of these injection times. So, we developed a screening paradigm, illustrated in Figure 5, that maximizes the possibility of detecting tissue biological changes associated with drug dosing. In addition, we broadened the approach to include assessment of other organs and tissues. The cocktail of probes is ideal for such broad tissue detection; cell death (AV-750) and inflammation (MMP-750) are obviously not limited to specific tissues, and transferrin receptors, good indicators of cellular iron metabolism (TfV-750), are expressed in a wide variety of normal tissues, including liver, spleen, brain, lung, muscle, testes, kidney, and heart (Kawabata et al., 2001).

Our screening approach uses as few as 6-8 mice per test compound (divided into 2 probe injection timepoints, each with 3-4 animals) with an additional 3-4 control animals that also receive AMT-750/AS-680.
We focused on two of our liver injury-inducing agents, TAA and RMP, which differ in liver injury mechanism as well as the kinetics of injury. The TAA group showed minimal changes when probes were injected at 2 h, however peak vascular leak and AMT-750 signal occurred when probes were injected at 24 h and imaged at 48 h. In contrast, the RMP group showed early AMT-750 signal, minimal late AMT-750 signal, and comparable vascular leak both early and late. Two-channel imaging on the IVIS SpectrumCT allowed the use of image math functions on the system software (Living Image®, PerkinElmer) to provide pixel-by-pixel ratios of AMT-750 to AS-680. Such ratio analysis allows correction of AMT750 image data for the contribution of non-specific tissue accumulation. This gives clear corrected fluorescent images (Figure 6) and reveals that a portion of the AMT-750 signal could be attributed to alterations in vascular leak into the tissues in the liver region. The corrected images removed early AMT-750 signal in TAA mice and almost completely removed late signal in the RMP mice. Quantitatively, both the AMT-750 and AS-680 probes showed statistically significant increases in liver region signal associated with the treatments (Fig. 7). The ratio data improved the quantification of the AMT-750 by removing contribution from vascular leak and was a useful comparator to the AS-680 data alone, the first showing corrected biological marker change and the second showing vascular leak.

To capture additional potential chemically-induced tissue effects, mice were euthanized following in vivo imaging and brain, lung, heart, liver, stomach, skin, abdominal fat, spleen, pancreas, intestines, and kidneys were removed. Ex vivo imaging of these tissues (Fig. 8), again acquiring both AMT-750 and AS-680 images, allowed detection of biological changes induced by chemical agent administration. For defined organs (i.e. brain, heart, lungs, liver, pancreas, spleen, stomach intestines, and kidneys), analysis was performed by measuring total fluorescence. To avoid tissue size bias in skin and abdominal fat tissue samples, analysis was performed by quantifying the fluorescence within standard-sized regions of interest (ROI) placed to capture the majority of the tissue area. RMP showed some interesting changes, including stomach enlargement (and increases in both AMT-750 and AS-680 due to this enlargement), increased signal in fat, and AMT-750-increases in intestines and kidneys. TAA showed late vascular leak changes in lung, intestines, kidneys, and fat; there were AMT-750-increases in lungs, liver, spleen, pancreas, intestines, and fat. Quantitation of these
ex vivo results (Fig. 9) showed statistically significant changes in the stomach, kidneys, and abdominal fat with RMP treatment. Ratio analysis further suggested modest changes in numerous tissues, including liver, in agreement with the generally elevated whole body signal seen with in vivo imaging. Interestingly, and in agreement with the study represented by Figure 4, the kidneys were much more affected by RMP than was the liver, revealing that although signal was significantly elevated in the liver region, overall abdominal region signal was dominated by greater increases in kidney fluorescence. In contrast, TAA induced a variety of modest vascular leak changes in a variety of tissues, however the predominant AMT-750 changes were seen in the liver and spleen once signal was corrected for non-specific vascular leak. Most of our findings, here using a single dose of chemical agent, are supported by previously published studies following repeated dosing of RMP (Poole et al., 1971; Bykova et al., 1977; Roszkowski et al., 1984; Katz and Lor, 1986; Zargar et al., 1990; Sodhi et al., 1997; Tassaduq et al., 2011; Chiba et al., 2013) or TAA (al-Bader et al., 2000; Wang et al., 2004).

**Histology assessment of single-dose drug effects on tissues identified by biomarker imaging.** In vivo fluorescence imaging of RMP- and TAA-treated mice suggested that these treatments induced significant biological changes that could be readily detected by our AMT-750 probe cocktail. Our previous studies with APAP had established that even a single bolus drug dose induce obvious tissue histology changes (Peterson, 2016), and additional studies had shown consistent detection of TAA- and CPZ-induced tissue damage with little or no obvious effects by RMP (data not shown). To understand the imaging results from RMP- and TAA-treated mice, in the context of overt tissue changes, we collected various tissues (liver, kidney, heart, spleen, stomach and fat) from treated animals and a trained pathologist assessed the H&E stained sections (Fig. 10). Liver results with TAA were reviewed by the pathologist as showing moderate necrosis following the single bolus dose of 300 mg/kg, whereas the same bolus dose of RMP induced no perceptible tissue changes. It is interesting to note that the four other sets of tissues in which we expected to see some level of tissue change, spleen (TAA), kidney (RMP), stomach (RMP), and fat (TAA & RMP), showed no overt signs of injury. This supports the expectation that biological changes would likely precede overt signs of tissue injury, when one
considers additional published data with repeated dosing in animals and human patients (Poole et al., 1971; Roszkowski et al., 1984; Katz and Lor, 1986; Zargar et al., 1990; al-Bader et al., 2000; Wang et al., 2004; Tassaduq et al., 2011; Kadir et al., 2013).
DISCUSSION

In vivo preclinical toxicology studies use living animals to assess potential drug-induced adverse effects, providing models in which potential toxicity is driven by the combined effects of drug distribution/metabolism, drug mechanistic efficacy, and the complex biology and physiology of a living animal. However, this complexity in animals may not always align completely with the complexity in humans, so there is always concern regarding the capability of preclinical toxicology assessment to predict clinical findings in humans. Clinical trials provide only a limited source of information regarding this “predictivity” because they are designed specifically to avoid adverse outcomes seen in animal studies. Rather, preclinical testing allows the establishment of a risk-assessment strategy in which the worst of the tested chemical compounds are considered too risky and never administered to humans, those with some adverse findings are used with caution and guidance from preclinical studies, and compounds with no apparent toxicity are progressed with healthy skepticism. It is in this way that preclinical toxicity testing of small and large molecule pharmaceuticals can play a valuable informative role in drug discovery and development, however this information often comes late in the discovery process. Generally, formal toxicology studies are large resource investments, predominantly employed at the late stages of drug discovery and are performed for advanced candidates to support regulatory filings. However, under this paradigm the high failure rate of new drugs, both in preclinical development and in clinical trials (Ahuja and Sharma, 2014), suggests a need for both better selection criteria for development candidates and earlier elimination of toxic compounds prior to selection as development candidates. Sensitive toxicology screening assays are needed that: (1) are designed for use earlier in the drug discovery process, during early preclinical lead selection; (2) are medium to high-throughput to allow parallel assessment of multiple compounds; (3) emphasize the sensitive detection of biological change rather than gross changes in tissue or in plasma biomarkers; and (4) offer the potential for broader assessment of additional non-hepatic tissues. Preclinical biological imaging strategies may be uniquely suited to addressing these needs.
NIR fluorescence preclinical imaging offers a useful approach to detect in situ dynamic changes in tissue biology through the use of highly stable, targeted, vascular, or protease-activated imaging probes. When considered in the context of either disease or toxicology/safety, imaging brings an aspect of non-invasive assessment of biological changes rather than gross physiological or ex vivo morphological changes. Imaging probes are designed to detect tissue biomarkers and accumulate directly at the local site of tissue injury, offering rapid multiplexing imaging of various biological readouts. NIR fluorescent probes have been used effectively to image various disease conditions modeled in preclinical species, including cancer (Weissleder and Ntziachristos, 2003; Montet et al., 2005; Kossodo et al., 2010; Bao et al., 2012), atherosclerosis (Chen et al., 2002; Deguchi et al., 2006), cardiac pathologies (Nahrendorf et al., 2007; Sosnovik et al., 2007), arthritis (Wunder et al., 2004; Peterson et al., 2010), CNS demyelination (Eaton et al., 2013) and osteoarthritis (Vermeij et al., 2014). Many of these same fluorescent imaging probes are currently being examined for their utility in toxicology/safety screening (Peterson, 2016). Our current studies show this to be a valuable approach, because some of the same biological/physiological processes and cellular players involved in various types of disease progression are also associated with drug-induced toxicity. To this end, we established an in vivo early screening liver injury protocol that is simple and fast, relying on a single bolus dose of test compounds. A cocktail of three different near infrared fluorescent imaging probes, AV-750 (cell death), MMP-750 (inflammation), and TfV-750 (metabolism) detects the effects of single bolus intraperitoneal doses of four different chemical agents known to induce liver injury by either hepatocellular, cholestatic, or mixed mechanisms. This technique provides robust quantitative analysis, and the ability to assess drug-induced liver injury non-invasively in vivo. The probe cocktail has the added advantage of also detecting damage occurring in a variety of other tissues, including kidney, spleen, and fat, further broadening the utility of the assessment (see Figs 8 & 9). This was a surprising finding for this probe cocktail, and it is currently under study to further understand its utility as a broad screening tool for whole body drug-induced tissue injury.

It is important to consider the practical application of our NIR fluorescence imaging approach for very early liver injury screening. Any effective approach needs to address mechanistic tissue injury kinetics, and we have
found that some compounds alter tissue biology within the first several hours after administration, whereas others require at least 24h. This is why our recommended protocol includes injecting the AMT-750 cocktail at both 2h and 24h in separate cohorts (for imaging at 26h and 48h respectively) to minimize the risk of an experimentally-biased false negative result. Any toxicology/safety screening protocol also needs to take into account dose dependence but also must provide a quick, practical assessment. To this end, we recommend using a single high-dose assessment of compounds at the highest tolerated dose, as well as the simultaneous injection of AS-680 with the AMT-750 cocktail. This dual imaging approach provides the maximal chance to detect liver changes, and also can separate vascular-damaging effects from tissue effects (discussed further below). It has been our approach to re-screen compounds at a lower dose if the high dose shows predominantly vascular damage, although this has mostly been to cleanly assess the utility of the AMT-750 cocktail without the complication of increased passive leakage into tissues. The absolute dose levels for testing may remain somewhat arbitrary (e.g. we set this as 300 mg/kg), as we envision these studies being performed as intraperitoneal injections in testing early lead compound series, prior to establishing efficacious doses and prior to SAR improvement of efficacy. In addition, researchers should also consider the assessment of both male and female mice if there are anticipated sex differences in drug-induced tissue injury or if there is an interest in assessing specific changes in signal in sexual organs. It is also our expectation that this imaging strategy could identify risky compounds for which the researcher can adopt a strategy of either 1) prioritization of compounds versus by in vivo risk assessment or 2) follow-up with additional conventional testing. An additional strategy would be to use this approach to follow a series of compounds through the discovery process as “spot checks” on adverse tissue effects, perhaps adopting dosage levels relative to efficacious doses.

It is also important to consider in vivo screening specificity as well as the relevance and utility of ex vivo tissue/organ imaging. The ability of the AMT-750 cocktail to detect changes even in non-hepatic tissues (applied to four chemical agents with well-defined injury in liver and other tissues) gave us the means to validate our imaging protocol. Our findings generally aligned well with known patterns of tissue injury: 1) detailed ex vivo tissue profiling of TAA showed effects in the liver as well as spleen, in agreement with
published studies, and 2) RMP showed effects predominantly in the kidneys and stomach, with broad effects on a number of other tissues, including liver, also in agreement with published studies. Normalization of AMT-750 results to AS-680 vascular imaging appears to offer some additional benefits in compensating for non-specific tissue accumulation due to vascular leak (Fig. 6 & 7). Histology assessment for such acute treatments did not detect gross tissue changes, except for TAA effects on the liver, however it is our experience that only hepatocellular toxicity-inducing treatments (including APAP, data not shown) show acute histological changes, whereas the more subtle biological changes associated with cholestasis may take much longer time to manifest at the tissue level. With regard to the accuracy of non-invasive in vivo imaging, in most cases the screening of supine, depilated mice by 2D fluorescence is highly effective in detecting drug-induced liver effects. However, there are some occasions with supine animal positioning in which high kidney signal, expected with RMP and CPZ (Berg and Bergan, 1976; Cuche et al., 1982; Katz and Lor, 1986), can be detected (see Fig. 4). This is only a confounding issue if the researcher does not perform ex vivo imaging of tissues following in vivo imaging. Doing both supine and prone imaging can help to provide proper interpretation of drug effects, and tomographic imaging, although lower through-put, can accurately separate liver and kidney fluorescence in one scan.

Of course there are no preclinical animal assessments that can exclude the possibility of false negative results as compared to results in humans, which would likely be due to species differences in metabolism or immune responses. In particular, idiosyncratic drug reactions (IDR), although not the most common type of adverse drug reaction, occur in few patients and are difficult to model or predict preclinically. The lack of clear drug dose-dependence and the association with delayed onset has generally suggested that IDRs are due to induced immunologic responses. However there are a number of manifestations apparently involving numerous potential mechanisms, including T cell-, neutrophil-, or eosinophil-driven rashes, systemic hematologic changes, and generalized or organ/tissue-specific autoimmunity. The strength of this imaging approach, however, is the fact that it sensitively detects drug-induced biological changes in tissues often in the absence of overt tissue morphology/phenotype changes (Figure 10). In recent studies, we have used the AMT-750 cocktail
to detect apparent 5-fluorouracil (5-FU)-induced heart changes, in the absence of tissue pathology, that may be
indicative of idiosyncratic 5-FU-induced cardiotoxicity (data not shown). In addition, the MMP activity
detected by this cocktail could be a useful biomarker for neutrophilia or eosinophilia associated with some
forms of IDR. Other forms of IDR, however, are associated with cognate immunity (i.e. T cell activation and
function) and may not be amenable to detection by AMT-750. Ongoing efforts with probes currently in
development for the assessment of immune function may yield tools for assessing more complex forms of
immune-driven IDR in repeat dosing preclinical rodent models.

It is important to note that optical imaging does not need to provide a solution for every toxicology question,
as there are a variety of currently validated approaches that cover these important needs. Clearly, more work
and more validation using a range of toxic compounds is essential to better understand the potential for false
positive and negative results. It is our belief that there may be instances in which optical imaging can provide
superior readouts, equivalent readouts with easier performance, or even qualitative readouts with greater
efficiency and consistency. With small numbers of animals, small quantities of test compound, and a small
amount of imaging probes, results can be obtained in vivo and ex vivo within just a couple of days. The
additional benefit of quick and easy detection of extra-hepatic tissue injury, from the same animals and with the
same imaging probes, further strengthens the utility of the approach. Our current belief is that the best fit for
optical imaging is in surrogate early risk-assessment screening of lead compounds, limiting the amounts of test
materials required and facilitating internal decisions with regard to which lead compounds are best suited for
optimization. The final assessment of regulatory-enabling toxicology studies will likely continue to be
performed by more conventional means in rats and larger appropriate species, but perhaps the outcomes of these
conventional assays will be more favorable for regulatory filing with the prior removal of high risk compounds
ey early in the discovery process.
Authorship Contributions

*Participated in research design:* Vasquez & Peterson

*Conducted experiments:* Vasquez

*Contributed new analytic approaches:* Peterson

*Performed data analysis:* Vasquez & Peterson

*Wrote or contributed to the writing of the manuscript:* Vasquez & Peterson
References


Footnotes

Financial Support: Support for these studies was provided by internal funds from PerkinElmer Inc, R&D.
Figure Legends

**Fig. 1.** Comparison of three optical imaging strategies for detecting liver fluorescence. APAP-treated (500 mg/kg) and control male C57BL/6 mice were injected 24 h later with AV750 and fluorescent images were acquired 2 h later on the IVIS SpectrumCT (PerkinElmer Inc). **A.** Representative images are shown of 1 treated and 1 control animal by 2D epifluorescence (upper panel), 2D transillumination fluorescence (middle panel), and 3D fluorescence tomography (lower panel), and regions of interest (ROI) were placed to capture signal in the liver and kidneys. Control region ROIs (not shown) were placed in the depilated right flank region for background subtraction. **B.** Quantification of liver and kidney AV750 fluorescent signal was determined in treated and control mice for each of the fluorescent imaging approaches.

**Fig. 2.** Assessment of four chemical compounds and three imaging probes in liver injury imaging. Whole mouse ventral epifluorescence imaging was used to detect accumulation of AV-750, MMP-645, and TfV-750 in the liver regions of different cohorts of mice at different times post-treatment. Mice (n = 3 per group) were injected with IP with the indicated drug doses and then injected IV with imaging probes at the indicated times (2, 5, 18, and 42h). Whole body epifluorescence images were acquired on the IVIS SpectrumCT 2 h after AV-750 or 24 h after MMP-645 and TfV-750. Representative individual mice are shown for each drug/probe combination, with the same mouse represented longitudinally, and this experiment is representative of three independent studies. White boxes indicate the liver regions quantified, and red-outlined yellow boxes show the optimal probe-injection times post-treatment.

**Fig. 3.** Multiple fluorescent probe profiling in the liver response to chemical insult. Quantification of liver signal from non-invasive imaging in Fig. 2 was determined using 2D ROI placement positioned to capture and quantify fluorescent signal in the liver region. Results are represented for the optimal probe/timepoint conditions as fold above background after standard 90% background thresholding to best illustrate profile trends for the different treatments.
**Fig. 4.** Validation of a three probe fluorescent cocktail for general detection of DILI. A cocktail of three imaging probes (AV750, MMP750, and TfV750) was optimized for 24 h imaging in mice treated with all four drugs (n = 3 per group). Drug dosed mice were injected with the imaging cocktail at two different times post-treatment (18 h for TAA and APAP; 2 h for CPZ and RMP), and all mice were imaged 24 h post-AMT-750 for both non-invasive liver assessment (upper left panel) and ex vivo tissues (lower left panel). Epifluorescence images of mice (left panel) of mice receiving optimal doses of RMP, CPZ, APAP, or TAA show liver region signal in comparison to control mice. Quantification of liver signal from non-invasive imaging (upper right panel) and ex vivo liver and kidney signal (lower right panel) were determined by ROI placement to capture the entire liver or individual tissues, and results were represented as total liver fluorescent signal +/- SE. Statistical significance was assessed by ANOVA with Dunnett’s post-test ((#p < 0.05, *p < 0.01, **p < 0.001, n = 3). Results are representative of multiple studies using either multiplex or individual probe imaging.

**Fig. 5.** Mouse acute liver injury screening paradigm. Depilated male BALB/c or C57BL/6 mice (Charles River Labs) are injected IP with DILI-inducing drugs. Separate cohorts of mice, at 2 and 18-24 h post-treatment, are then injected with imaging probes (AMT-750 and AS-680) for imaging 24 h later to detect biological changes within damaged tissue.

**Fig. 6.** Ratio of AMT-750 to vascular leak (AS-680) to correct for non-specific accumulation of AMT-750 in tissues. Mice (n = 3 per group) pre-treated with TAA or RMP were co-injected with the AMT-750 cocktail and AS-680, a well-established vascular leak imaging probe, to allow normalization of AMT-750 data. Whole mouse epifluorescence imaging was used to detect accumulation of the 680 nm and 750 nm probes in the liver regions of different cohorts of mice post-treatment. A. Epifluorescence images of AS-680 and B. AMT-750 (middle panel) signal in controls and in treated mice at two times post-treatment. C. Normalized ratio images (AMT-750:AS-680) were generated on the IVIS SpectrumCT Living Image 4.5 software. White boxes indicate
the liver regions analyzed for fluorescent signal. Results are representative of three studies using probe cocktail imaging.

**Fig. 7.** Quantification of AMT-750 : AS-680 ratios for quantification of DILI. Single channel quantification of liver region fluorescence signal from non-invasive imaging was determined by ROI placement to capture the entire liver. Results are represented with 90% of negative control liver signal subtracted. **A.** Results from AMT-750 (upper panel) and AS-680 (lower panel) signal are represented as radiant efficiency without correction. **B.** Ratio of AMT-750 to AS-680, using Living Image 4.5 image math functions was performed to correct AMT-750 results for non-specific vascular leak contribution to the overall signal. Results are expressed as ratios of AMT-750 to AS680 subsequently normalized to set average control ratios to 1. Statistical significance was assessed by ANOVA with Dunnett’s post-test ((#p < 0.05, *p < 0.01, **p < 0.001, n = 3).

**Fig. 8.** Ex vivo AMT-750 and AS-680 imaging of excised tissues from control, RMP-treated, and TAA-treated mice. Single channel images of excised liver, brain, lung, heart, stomach, skin, fat, spleen, pancreas, intestine, and kidney tissues were acquired for **A.** control, **B.** RMP treatment, and **C.** TAA treatment with both AS-680 (upper panels) and AMT-750 (lower panels) imaging probes. Images were acquired for the optimal timepoints for each treatment, 2 h for RMP and 24 h for TAA. AMT-750 images were optimized for liver visualization, which led to saturation of kidney signal (mostly due to known kidney clearance of AV-750). Insets provide optimized images for the kidney, revealing enhanced signal in kidneys from RMP-treated mice.

**Fig. 9.** Quantification of fluorescence in excised tissues from control, RMP-treated, and TAA-treated mice. ROIs were placed to quantify fluorescence levels in liver, brain, lung, heart, stomach, skin, fat, spleen, pancreas, intestine, and kidney tissues from control, TAA-treated, and RMP-treated mice that had been injected with both AS-680 and AMT-750. **A.** AS-680, **B.** AMT-750, and **C.** AMT-750 to AS-680 ratio fluorescence datasets.
were quantified, and data was normalized. Results are represented as ratio to control +/- SEM, and statistical significance was assessed by ANOVA with Dunnett’s post-test ((#p < 0.05, *p < 0.01, **p < 0.001, n = 3). Results are representative of multiple studies using either multiplex or individual probe imaging.

**Fig. 10.** Histological assessment of tissues from control, RMP-treated, and TAA-treated mice. Liver, kidney, heart, spleen, stomach, and fat tissues were collected from control, RMP-treated, and TAA-treated BALB/c mice. Tissues were fixed in 10% neutral buffered formalin for 24h at at 20°C, followed by storage in 70% ethanol. Tissues were then paraffin-embedded, sectioned (4 µm), and stained with hematoxylin & eosin (H&E) for general evaluation of pathologic changes. Results were assessed by a pathologist, and the only gross abnormality seen across the range of tissues was moderate necrosis induced by TAA (see red-outlined image).
Tables

Table 1. Toxicology tissue changes and NIR imaging probes

<table>
<thead>
<tr>
<th>Tox/Tissue</th>
<th>Biological tissue response</th>
<th>Potential Imaging probes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General markers</strong></td>
<td></td>
<td><strong>MMPSense® 680 &amp; 750 FAST®</strong></td>
</tr>
<tr>
<td>Inflammation</td>
<td></td>
<td><strong>ProSense® 680, 750EX, &amp; 750 FAST</strong></td>
</tr>
<tr>
<td>Neutrophil Elastase</td>
<td></td>
<td>Neutrophil Elastase 680 FAST</td>
</tr>
<tr>
<td>Apoptosis/Necrosis</td>
<td></td>
<td><strong>Annexin-Vivo™ 750</strong></td>
</tr>
<tr>
<td>Vascular changes</td>
<td></td>
<td><strong>AngioSense® 680EX &amp; 750EX</strong></td>
</tr>
<tr>
<td><strong>Liver-specific</strong></td>
<td>Metabolism</td>
<td><strong>Transferrin-Vivo™ 750</strong></td>
</tr>
<tr>
<td><strong>Kidney-specific</strong></td>
<td>Glomerular filtration</td>
<td><strong>GFR-Vivo™ 680</strong></td>
</tr>
<tr>
<td>Renin-angiotensin system</td>
<td></td>
<td>ReninSense 680 FAST</td>
</tr>
<tr>
<td><strong>Stomach-specific</strong></td>
<td>Gastric Emptying</td>
<td><strong>GastroSense™ 680</strong></td>
</tr>
<tr>
<td><strong>Soft Tissue Calcification</strong></td>
<td>Calcium deposition</td>
<td><strong>OsteoSense® 680 &amp; 750</strong></td>
</tr>
<tr>
<td>Cathepsin K activity</td>
<td></td>
<td>Cat K 680 FAST</td>
</tr>
</tbody>
</table>

* Underlined probes indicate those that are commercially available with some validation data for use in preclinical drug-induced tissue injury applications (Peterson, 2016)
Figure 2

Control  300 mg/kg RMP  100 mg/kg CPZ  300 mg/kg APAP  300 mg/kg TAA

AV-750

MMP-645

TfV-750

Fluorescence Radiant Efficiency ($\times 10^9$)
Figure 3

![Graph showing relative liver fluorescence for different treatments. The x-axis represents different treatments: Control, RMP - 2h, CPZ - 42h, APAP - 22h, and TAA - 42h. The y-axis represents relative liver fluorescence. The graph compares the effects of AV-750, MMP-645, and TfV-750.]
Figure 4

In Vivo IVIS Imaging

Quantification
Total Liver Region Fluorescence

Ex Vivo Tissue Fluorescence

Whole Body
Liver Tissue
Kidney Tissue

Control, 2h RMP, 18h CPZ, 22h APAP, 18h TAA

(Radiant Efficiency X 10^9)
Figure 5

Mouse Acute Liver Injury Screening Paradigm

- SKH1-E, BALB/c, or C57BL/6 mice
- Treatment IP 100-500 mg/kg
- \( \text{AngioSense 680, AV-750/MMP-750/TfV-750 (AMT) Cocktail} \)
- Time post-drug (h):
  - 0, 2, 24, 48
- Image
- Depilated region
- Liver Injury
- In Vivo Fluorescence Imaging
- Ex Vivo Tissue Fluorescence Profiling
Figure 7

A. Single Channel Analysis

AMT-750 Cocktail

B. Ratio Analysis

AMT-750 : AS-680 Average Ratio
Figure 8

A  Control  

B  RMP - 2h  

C  TAA - 24h  

AS-680

Lung  
Stomach  
Liver  
Skin  
Fat

Brain  
Heart  
Spleen  
Pancreas  
Intestines  
Kidneys

AMT-750

Kidneys 1/5X

Kidneys 1/5X

Kidneys 1/5X

(Radiant Efficiency X 10^9)
Figure 10

Liver

Kidney

Heart

Spleen

Stomach

Fat

Control RMP TAA

This article has not been copyedited and formatted. The final version may differ from this version.